Eli Lilly Reports 18.5% BMI Reduction With Tirzepatide in Adolescents

Share on Social Media

Eli Lilly's tirzepatide reduced BMI by 18.5% in adolescents with obesity in the Phase 3 SURMOUNT-ADOLESCENTS trial.
Image: Pexels

Eli Lilly’s tirzepatide reduced BMI by 18.5% over 72 weeks in adolescents with obesity in the Phase 3 SURMOUNT-ADOLESCENTS trial published in JAMA.

Written By: Anamika Koshti, PharmD

Reviewed By: Pharmacally Editorial Team

Eli Lilly’s once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide reduced body mass index (BMI) by 18.5% over 72 weeks in adolescents with obesity or overweight accompanied by an obesity-related complication, compared with a 0.5% increase with placebo. The findings from the Phase 3 SURMOUNT-ADOLESCENTS trial (NCT06075667) were published in JAMA on November 15, 2026, and presented at ObesityWeek 2026. The study demonstrated a 19.0-percentage-point difference between treatment groups, supporting tirzepatide’s potential as an investigational pharmacological option for adolescent obesity.

Trial Design: 160 Adolescents Randomized Across Six Countries

The randomized, double-blind, placebo-controlled trial enrolled 160 adolescents aged 12 to under 18 years across 31 sites in Canada, the Czech Republic, Israel, Italy, Poland and the US. Participants were randomized 2:1 to once-weekly subcutaneous tirzepatide (n=109) or placebo (n=51), alongside healthy lifestyle intervention.

The study comprised a 2-week screening period, a 12-week lifestyle intervention lead-in, a 20-week dose-escalation period, a 52-week treatment-maintenance period and a 4-week safety follow-up. Tirzepatide dosing began at 2.5 mg and increased in 2.5-mg increments every four weeks to a maximum tolerated dose of 5, 10 or 15 mg. The overall study duration was approximately 90 weeks.

Mean baseline age was 14.6 years, BMI was 38.6 and body weight was 109.7 kg. Approximately 61.9% of participants were female.

Primary Endpoint: BMI Decreased by 18.5% at Week 72

Under the treatment-regimen estimand, which evaluates the effect of the assigned treatment strategy regardless of treatment discontinuation or initiation of prohibited obesity treatments, BMI decreased by 18.5% with tirzepatide (95% CI, −21.2 to −15.7) and increased by 0.5% with placebo. The estimated treatment difference was −19.0 percentage points (95% CI, −23.9 to −14.1; P less than .001).

The efficacy estimand, which models the hypothetical scenario in which participants continued their assigned treatment for 72 weeks without intercurrent events, showed a larger BMI reduction of 21.4% with tirzepatide versus a 0.4% increase with placebo, representing a 21.7-percentage-point difference. The distinction is important because the efficacy estimate does not reflect the same treatment-discontinuation scenario as the primary analysis.

Secondary Outcomes: BMI Thresholds and Physical Function Improve

All 10 key secondary endpoints significantly favored tirzepatide. BMI reductions of at least 5%, 10%, 15% and 20% were achieved by 79.6%, 71.4%, 63.4% and 48.1% of participants, respectively, compared with 28.5%, 19.5%, 12.4% and 7.9% with placebo.

Body weight decreased by 16.9% with tirzepatide, while the placebo group experienced a 2.2% increase. Additionally, 53.5% of tirzepatide-treated participants achieved a BMI below the age- and sex-specific 95th percentile, compared with 7.1% receiving placebo.

The treatment also improved physical functioning. The Impact of Weight on Quality of Life-Kids (IWQOL-Kids) Physical Comfort score improved by 10.3 points more than placebo (P=.002). Additional improvements were observed in cardiometabolic measures, including systolic and diastolic blood pressure, fasting glucose, HbA1c, fasting insulin and several lipid parameters.

Safety and Tolerability: Gastrointestinal Events and Discontinuations

In the safety population (n=108 for tirzepatide; n=51 for placebo), adverse events occurred in 95.4% of tirzepatide-treated participants and 82.4% of placebo recipients. Gastrointestinal events were most common, affecting 81.5% and 54.9%, respectively. Vomiting (50.9% versus 13.7%), nausea (50.0% versus 23.5%) and diarrhea (45.4% versus 25.5%) were the most frequently reported gastrointestinal events and were generally mild to moderate.

Adverse events led to treatment discontinuation in 9.3% of tirzepatide recipients, compared with none receiving placebo. Serious adverse events occurred in 7.4% versus 3.9%, with no deaths.

Depression or suicidal ideation was reported as an adverse event in five tirzepatide-treated participants (4.6%) and one placebo-treated participant (2.0%). The authors reported that no suicidal ideation events were severe, no participants discontinued treatment because of suicidal ideation, and all participants reporting suicidal ideation had a psychiatric history. Height and pubertal progression were similar between treatment groups over the study period.

Clinical Context: Adult Tirzepatide and Adolescent Semaglutide Results

The authors contextualized the findings alongside the approximately 20% body-weight reduction reported in adults receiving tirzepatide in the SURMOUNT-1 trial. They also compared the results with STEP TEENS (NCT04102189), in which semaglutide 2.4 mg reduced BMI by 16.1% compared with a 0.6% increase with placebo at 68 weeks. However, the adolescent and adult findings involve different outcome measures, while the semaglutide and tirzepatide findings represent indirect comparisons across separate trials. Neither comparison establishes tirzepatide’s superiority over semaglutide.

Clinical Interpretation: Longer-Term Growth and Safety Monitoring Remain Important

SURMOUNT-ADOLESCENTS provides randomized evidence of substantial BMI reduction with tirzepatide alongside lifestyle intervention. However, overall treatment discontinuation occurred in 21.1% of the tirzepatide group and 31.4% of the placebo group. Adverse events were the most common reason for discontinuation with tirzepatide, whereas lack of efficacy was the leading reason with placebo.

The study’s limitations include its relatively small population, limited racial and ethnic diversity, enrollment of only one participant with type 2 diabetes and one with overweight, and limited representation of adolescents at earlier pubertal stages. Approximately 62% of female and 43% of male participants had reached Tanner stage 5 at baseline, restricting conclusions about treatment effects on growth and maturation during earlier pubertal stages.

While these findings position tirzepatide as a promising candidate for adolescent obesity treatment, longer-term follow-up is needed to assess the durability of BMI reduction after treatment cessation and establish its safety throughout growth and puberty. Further clinical evidence and regulatory evaluation will be necessary to determine its role in adolescent obesity management.

Reference

Kelly AS et al. Tirzepatide in Adolescents with Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial. JAMA. Published online November 15, 2026. doi:10.1001/jama.2026.23420.

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight with Weight-Related Comorbidities, ClinicalTrials.gov ID NCT06075667

About the Writer

Anamika Koshti (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, and evidence-based medicine. She has authored peer-reviewed publications on Alzheimer’s disease and PCOS, presented research at national conferences, and gained hands-on experience in medical content development and clinical data interpretation. She is committed to translating complex medical research into accurate, accessible content for healthcare professionals and patients.


Share on Social Media
Scroll to Top